e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Pulmonary circulation: clinical treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH)
A. Waxman, A. Opotowsky, L. Lawler, D. Systrom (Boston, United States Of America)
Source:
Annual Congress 2013 –Pulmonary circulation: clinical treatment
Session:
Pulmonary circulation: clinical treatment
Session type:
Thematic Poster Session
Number:
4059
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Waxman, A. Opotowsky, L. Lawler, D. Systrom (Boston, United States Of America). An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH). Eur Respir J 2013; 42: Suppl. 57, 4059
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH)
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
Patient perspectives on exercise training in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Atorvastatin in Pulmonary Arterial Hypertension (APATH) study
Source: Eur Respir J 2012; 40: 67-74
Year: 2012
Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016
Baseline hemodynamic predictors of treatment response in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension
Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension
Year: 2005
Effects of pulmonary rehabilitation (PR) in idiopathic pulmonary arterial hypertension (PAHI)
Source: Annual Congress 2013 –The latest insights in pulmonary rehabilitation (part 2)
Year: 2013
Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Exercise right heart catheterisation in the diagnosis of pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Safety related to maximal cardiopulmonary exercise testing in patients with pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016
Recovery from dynamic exercise dissociates ventilatory from pulmonary gas exchange responses in patients with chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2013 –Mechanisms contributing to exercise limitation in health and respiratory, cardiac and pulmonary vascular diseases
Year: 2013
Riociguat improves excessive exercise ventilation in patients with inoperable chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers
Year: 2013
Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016
Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients
Source: Eur Respir J 2004; 24 : 580-586
Year: 2004
Afterload reduction governs improvement in RV systolic function and ventriculo-arterial adaptation in patients with pulmonary arterial hypertension (PAH) undergoing rapid dose escalation of treprostinil
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases
Year: 2016
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept